国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Business / Companies

Guilin at forefront in battle against malaria

By Wang Hongyi (China Daily) Updated: 2015-11-09 09:47

Since 2000, global mortality rates among malaria patients have dropped by 47 percent. In Africa, the rate has come down by 54 percent for adults and 58 percent for children.

GPSC has played an important role, along with major global pharmaceutical companies such as Novartis in Switzerland and Sanofi-Aventis in France, in fighting malaria.

The Chinese company was at the forefront in developing the innovative artesunate vaccine, Artsun, the first of its kind, to replace quinine injections. The WHO has compared it to the "gold standard" in the battle against malaria.

Artsun is now registered in more than 30 countries and regions and has a 90 percent market share in treating servere malaria.

During the past three years, GPSC has supplied 23.8 million units of the vaccine globally, saving more than 3.4 million people from the scourge of malaria.

"This is an innovative drug that was developed in China," Guo Guangchang, chairman of Fosun Group, said.

During the past decade, 13 anti-malaria drugs developed by GPSC have been approved by the WHO, including three which are injected and 10 in oral tablets.

The company's products account for 80 percent of China's anti-malaria drug exports.

In the first three quarters of this year, Fosun Pharmaceutical, which includes GPSC, reported revenue of 9 billion yuan ($1.41 billion), a rise of 4.76 percent compared to the same period in 2014.

Further financial details have yet to be released. The company's products include metabolism and digestive system drugs, and vaccines, as well as GPSC's brands.

"At present, Guilin Pharma is building a new manufacturing site which will comply with (international) standards," GPSC said.

"In future, we will have a production capacity of over 15 billion tablets/capsules per year to meet the needs of both domestic and global markets." the company added.

Fosun Pharmaceutical also plans to expand its research and development program by working alongside institutions and other organizations.

"There should be more cooperation with research institutes and organizations," Chen Qiyu, chairman of Fosun Pharmaceutical, said.

"This would help create a much larger platform, allowing us to do a better job globally."

Previous Page 1 2 Next Page

Hot Topics

Editor's Picks
...
西吉县| 曲靖市| 宣威市| 攀枝花市| 民丰县| 眉山市| 邓州市| 光泽县| 运城市| 铜川市| 许昌县| 行唐县| 武隆县| 法库县| 丘北县| 庐江县| 云林县| 凌云县| 永和县| 蒲江县| 乌拉特前旗| 嘉善县| 峨眉山市| 余干县| 台中县| 万载县| 靖边县| 苍南县| 富民县| 孟连| 弋阳县| 日喀则市| 方正县| 宜州市| 青铜峡市| 都昌县| 县级市| 巢湖市| 北碚区| 横山县| 河东区|